Drugs / Coenzyme I
Coenzyme I
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05849519 | Feb 2022 → Feb 2024 | sudden sensorineural hearing loss | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06590844 | Dec 2023 → Mar 2026 | hepatocellular carcinoma | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07328100 | Jan 2026 → Jun 2027 expected | arterial disorder | Shanghai 10th People's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coenzyme I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05849519 ↗ |
| Known as | NAD+ | “Coenzyme I (nicotinamide adenine dinucleotide, NAD+)” NCT06590844 ↗ |
| Known as | nicotinamide adenine dinucleotide | “Coenzyme I (nicotinamide adenine dinucleotide, NAD+)” NCT06590844 ↗ |
| Route | Intramuscular | “Procedure:Coenzyme I for Injection,5mg，im，qd；Nacl，2ml，im，qd.” NCT05849519 ↗ |